See more : Regeneron Pharmaceuticals, Inc. (REGN) Income Statement Analysis – Financial Results
Complete financial analysis of Peptron, Inc. (087010.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Peptron, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pilgrim Petroleum Corporation (PGPM) Income Statement Analysis – Financial Results
- Maanshan Iron & Steel Company Limited (600808.SS) Income Statement Analysis – Financial Results
- BlackRock MuniHoldings New Jersey Quality Fund, Inc. (MUJ) Income Statement Analysis – Financial Results
- Beijing Energy International Holding Co., Ltd. (0686.HK) Income Statement Analysis – Financial Results
- Aeon Global Health Corp. (AGHC) Income Statement Analysis – Financial Results
Peptron, Inc. (087010.KQ)
About Peptron, Inc.
Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.34B | 5.81B | 6.62B | 3.12B | 1.80B | 3.86B | 3.22B | 3.13B | 2.81B | 2.48B | 3.10B | 3.10B |
| Cost of Revenue | 2.29B | 7.28B | 5.32B | 5.05B | 3.64B | 2.57B | 2.13B | 2.03B | 2.01B | 1.39B | 1.77B | 2.13B |
| Gross Profit | 1.05B | -1.47B | 1.31B | -1.93B | -1.84B | 1.30B | 1.08B | 1.10B | 806.25M | 1.09B | 1.33B | 974.96M |
| Gross Profit Ratio | 31.53% | -25.25% | 19.75% | -61.74% | -102.04% | 33.58% | 33.63% | 35.26% | 28.67% | 44.02% | 42.89% | 31.44% |
| Research & Development | 11.44B | 9.40B | 12.77B | 12.24B | 8.09B | 6.07B | 3.74B | 2.77B | 2.01B | 1.99B | 1.92B | 765.12M |
| General & Administrative | 1.52B | 1.35B | 1.42B | 1.26B | 2.65B | 2.52B | 1.61B | 1.31B | 1.10B | 1.05B | 22.22M | 17.95M |
| Selling & Marketing | 1.34B | 1.42B | 1.63B | 1.35B | 591.74M | 552.14M | 450.36M | 566.70M | 502.12M | 558.92M | 303.81M | 209.67M |
| SG&A | 5.21B | 4.91B | 5.08B | 4.32B | 3.33B | 3.13B | 2.12B | 1.90B | 1.65B | 1.61B | 1.19B | 1.08B |
| Other Expenses | 0.00 | -686.00K | -241.69M | -701.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.02B | 14.31B | 17.85B | 16.56B | 11.42B | 9.20B | 5.86B | 4.67B | 3.66B | 3.61B | 2.65B | 2.31B |
| Cost & Expenses | 18.94B | 21.60B | 23.17B | 21.60B | 15.06B | 11.77B | 7.99B | 6.69B | 5.66B | 5.00B | 4.42B | 4.44B |
| Interest Income | 242.07M | 422.61M | 475.41M | 141.20M | 424.62M | 607.79M | 513.74M | 333.65M | 39.55M | 548.58M | 741.51M | 1.22B |
| Interest Expense | 396.04M | 279.66M | 36.84M | 95.46M | 20.16M | 0.00 | 2.00 | 350.00 | 92.28M | 590.27M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.89B | 5.05B | 3.51B | 3.27B | 2.65B | 899.51M | 594.22M | 602.23M | 597.96M | 578.39M | 562.86M | 1.14B |
| EBITDA | -12.65B | -9.73B | -11.74B | -14.34B | -10.05B | -7.01B | -4.18B | -2.43B | -2.07B | -1.90B | -1.38B | -124.69M |
| EBITDA Ratio | -378.54% | -184.50% | -196.78% | -487.60% | -588.70% | -181.43% | -129.99% | -94.61% | -80.08% | -81.77% | -44.40% | -6.03% |
| Operating Income | -15.60B | -15.78B | -16.55B | -18.48B | -13.25B | -7.91B | -4.77B | -3.56B | -2.85B | -2.61B | -1.94B | -1.32B |
| Operating Income Ratio | -466.89% | -271.44% | -249.76% | -592.26% | -735.90% | -204.72% | -148.47% | -113.85% | -101.34% | -105.06% | -62.54% | -42.66% |
| Total Other Income/Expenses | -337.90M | 159.66M | 95.47M | -973.49M | -4.92B | 4.21B | 301.01M | 467.91M | 85.48M | -460.03M | -117.07M | -1.24B |
| Income Before Tax | -15.94B | -15.07B | -15.28B | -18.34B | -17.63B | -3.70B | -4.47B | -3.10B | -2.76B | -3.07B | -2.06B | -2.56B |
| Income Before Tax Ratio | -477.00% | -259.15% | -230.71% | -587.53% | -978.62% | -95.73% | -139.11% | -98.90% | -98.31% | -123.59% | -66.31% | -82.55% |
| Income Tax Expense | -18.94M | -4.21M | -241.75M | 46.81M | 91.42M | 28.90M | -46.02M | 94.71M | -34.30M | 23.00M | 1.43M | 0.00 |
| Net Income | -15.92B | -15.06B | -15.04B | -18.38B | -17.72B | -3.73B | -4.43B | -3.19B | -2.73B | -3.05B | -2.06B | -2.56B |
| Net Income Ratio | -476.43% | -259.08% | -227.07% | -589.03% | -983.70% | -96.48% | -137.68% | -101.93% | -97.09% | -122.66% | -66.36% | -82.55% |
| EPS | -773.61 | -730.25 | -729.24 | -1.20K | -1.10K | -230.93 | -276.97 | -207.75 | -214.47 | -864.00 | -662.00 | -831.00 |
| EPS Diluted | -773.61 | -730.25 | -729.24 | -1.20K | -1.10K | -219.08 | -276.97 | -207.75 | -214.47 | -864.00 | -662.00 | -831.00 |
| Weighted Avg Shares Out | 20.58M | 20.63M | 20.63M | 15.37M | 16.13M | 16.13M | 15.98M | 15.36M | 12.73M | 3.53M | 3.11M | 3.08M |
| Weighted Avg Shares Out (Dil) | 20.58M | 20.63M | 20.63M | 15.37M | 16.13M | 17.01M | 15.98M | 15.36M | 12.73M | 3.53M | 3.11M | 3.08M |
Source: https://incomestatements.info
Category: Stock Reports